Cancer Moonshot Round 2 Focuses On Screening; Pharma To Participate In New Summit

The initial moonshot aimed to increase cancer research while the reboot seeks to boost screenings to reduce death rate. New cancer cabinet mirrors previous task force. Biopharmaceutical companies are to participate in summit to highlight new commitments.

Moonshot
President Biden relaunches the Cancer Moonshot program • Source: Alamy

In reigniting the Cancer Moonshot initiative, President Biden called on the biopharmaceutical industry to develop new treatments, make drugs more affordable, and share knowledge. But while the program launched in 2016 had specific goals to increase research, the reboot is primarily targeting cancer screening.

At a 2 February briefing in the White House East Room, Biden said the goal was to “supercharge the Cancer Moonshot” to cut the death rate from cancer by 50% over the next 25 years and provide a more supportive environment for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.